SCHEMBL17329007

SCHEMBL17329007

Clc1ccnc2occc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 1/20 0.41
PRKCI P41743 1/20 0.41
DAO P14920 1/20 0.34
KDM4E B2RXH2 2/20 0.33
MEN1 O00255 1/20 0.33
ALDH1A1 P00352 1/20 0.33
KMT2A Q03164 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
FADS1 O60427 1/20 0.33
KCNA3 P22001 1/20 0.32
MMP14 P50281 1/20 0.31
NR4A2 P43354 1/20 0.31
BRD4 O60885 1/20 0.31
LMNA P02545 1/20 0.31
HSP90AA1 P07900 1/20 0.31
MAPT P10636 1/20 0.31
METAP2 P50579 1/20 0.31
METAP1 P53582 1/20 0.31
HTT P42858 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29807239 1.00 AXL (0.41) AXLPRKCIDAOKDM4EMEN1
SCHEMBL30731217 0.73 PRKCI (0.41) PRKCIDAOKCNA3
SCHEMBL22554158 0.73 PRKCI (0.41) PRKCIDAOKCNA3
SCHEMBL22270836 0.73 KCNA3 (0.32) ALDH1A1KCNA3MAPTSMN1; SMN2
SCHEMBL14216744 0.73 CDK5 (0.32) KDM4EKCNA3
SCHEMBL899214 0.73 NCF1 (0.43) KCNA3MMP14NR4A2HSP90AA1SLC40A1
SCHEMBL12143638 0.73 CCR1 (0.48) KDM4EMEN1ALDH1A1KMT2AKCNA3
SCHEMBL8570710 0.72 KCNA3 (0.33) KCNA3
SCHEMBL1785195 0.71 PDE4A (0.42) AXLKDM4EMEN1ALDH1A1KMT2A
SCHEMBL25253882 0.68 SLC40A1 (0.35) AXLKCNA3SLC40A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12473284-B2 Small molecule inhibitors of ULK1 MEMORIAL SLOAN KETTERING CANCER CENTER (US) 2025-11-18 US disclosed
US-20240150293-A1 SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS VERNALIS (R&D) LTD (GB) 2024-05-09 US disclosed
EP-4277892-A1 SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS Les Laboratoires Servier (FR) 2023-11-22 EP disclosed
CN-116940552-A Spirocyclic hexane derivatives, pharmaceutical compositions containing them and their use as anti-apoptotic inhibitors 法国施维雅药厂 2023-10-24 CN disclosed
US-20230117572-A1 SMALL MOLECULE INHIBITORS OF ULK1 MEMORIAL SLOAN KETTERING CANCER CENTER 2023-04-20 US disclosed
US-20230117572-A1 SMALL MOLECULE INHIBITORS OF ULK1 MEMORIAL SLOAN KETTERING CANCER CENTER 2023-04-20 US disclosed
WO-2022152705-A1 SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS LES LABORATOIRES SERVIER (FR) 2022-07-21 WO disclosed
US-20210317134-A1 UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF RAPT THERAPEUTICS INC (US) 2021-10-14 US disclosed
WO-2021138331-A2 SMALL MOLECULE INHIBITORS OF ULK1 MEMORIAL SLOAN KETTERING CANCER CENTER (US) 2021-07-08 WO disclosed
WO-2021138331-A2 SMALL MOLECULE INHIBITORS OF ULK1 MEMORIAL SLOAN KETTERING CANCER CENTER (US) 2021-07-08 WO disclosed
EP-2955185-B1 POLYCYCLIC SUBSTITUTED PYRAZOLE KINASE ACTIVITY INHIBITORS AND USE THEREOF SHANGHAI FOSUN PHARMACEUTICAL DEV CO LTD (CN) 2021-01-06 EP disclosed
CN-107098903-B Polycyclic substituted pyrazole kinase activity inhibitor and application thereof 上海复星医药产业发展有限公司 2020-07-17 CN disclosed
US-9550792-B2 Polycyclic substituted pyrazole kinase activity inhibitors and use thereof SHANGHAI FOSUN PHARMACEUTICAL DEVELOPMENT CO., LTD. (CN) 2017-01-24 US disclosed
US-20150368259-A1 Polycyclic Substituted Pyrazole Kinase Activity Inhibitors and Use Thereof SHANGHAI FOSUN PHARMACEUTICAL DEVELOPMENT CO., LTD. (CN) 2015-12-24 US disclosed
EP-2955185-A1 POLYCYCLIC SUBSTITUTED PYRAZOLE KINASE ACTIVITY INHIBITORS AND USE THEREOF China Pharmaceutical University (CN) 2015-12-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230117572-A1 SMALL MOLECULE INHIBITORS OF ULK1 ULK1, ULK2, ULK3 AXL 779/4885PRKCI 1163/4885DAO 4763/4885
US-20240150293-A1 SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS BCL2, BAX, BCL2A1 AXL 4248/4885PRKCI 1765/4885DAO 4782/4885
US-12473284-B2 Small molecule inhibitors of ULK1 ULK1, ULK2, ULK3 AXL 779/4885PRKCI 1163/4885DAO 4763/4885
US-20210317134-A1 UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF USP7, SENP7, USP8 AXL 2071/4885PRKCI 1821/4885DAO 2216/4885
US-20150368259-A1 Polycyclic Substituted Pyrazole Kinase Activity Inhibitors and Use Thereof MAP3K5, MAP3K19, MAP3K3 AXL 413/4885PRKCI 159/4885DAO 1680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.